Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 307 (5707), 223-7

A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium Tuberculosis

Affiliations
Clinical Trial

A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium Tuberculosis

Koen Andries et al. Science.

Abstract

The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.

Comment in

Similar articles

See all similar articles

Cited by 512 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback